Financials Agilent Technologies, Inc.

Equities

A

US00846U1016

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 01:30:01 18/06/2024 am IST			After market 04:45:01 pm
131.8 ^USD	+1.52%		130.5	-1.01%

12/06	Agilent Technologies Insider Sold Shares Worth $1,999,262, According to a Recent SEC Filing	MT
05/06	Agilent Technologies Insider Sold Shares Worth $254,540, According to a Recent SEC Filing	MT

Valuation

Fiscal Period: October	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	23,442	31,475	47,676	40,957	30,245	38,463	-	-
Enterprise Value (EV) ¹	24,467	32,393	48,830	42,673	31,390	39,341	39,475	41,059
P/E ratio	22.5 x	44.4 x	40 x	33.1 x	24.7 x	29 x	26.6 x	24.2 x
Yield	0.87%	0.71%	0.49%	0.61%	-	0.71%	0.75%	0.83%
Capitalization / Revenue	4.54 x	5.9 x	7.54 x	5.98 x	4.43 x	5.95 x	5.62 x	5.26 x
EV / Revenue	4.74 x	6.07 x	7.73 x	6.23 x	4.59 x	6.09 x	5.77 x	5.61 x
EV / EBITDA	18.6 x	24.3 x	29.6 x	20.8 x	16.1 x	20.9 x	19 x	18 x
EV / FCF	28.3 x	40.4 x	37.6 x	41.8 x	21.3 x	29.5 x	25.5 x	23.7 x
FCF Yield	3.54%	2.48%	2.66%	2.39%	4.7%	3.39%	3.92%	4.21%
Price to Book	5.07 x	6.54 x	8.83 x	7.8 x	5.23 x	6.17 x	5.44 x	4.67 x
Nbr of stocks (in thousands)	3,09,468	3,08,310	3,02,723	2,96,041	2,92,587	2,91,761	-	-
Reference price ²	75.75	102.1	157.5	138.4	103.4	131.8	131.8	131.8
Announcement Date	25/11/19	23/11/20	22/11/21	21/11/22	20/11/23	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: October	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	5,163	5,339	6,319	6,848	6,833	6,460	6,845	7,319
EBITDA ¹	1,315	1,335	1,650	2,051	1,955	1,885	2,080	2,276
EBIT ¹	1,202	1,211	1,523	1,857	1,875	1,709	1,886	2,061
Operating Margin	23.28%	22.68%	24.1%	27.12%	27.44%	26.45%	27.56%	28.16%
Earnings before Tax (EBT) ¹	919	842	1,360	1,504	1,339	1,356	1,451	1,560
Net income ¹	1,071	719	1,210	1,254	1,240	1,310	1,425	1,549
Net margin	20.74%	13.47%	19.15%	18.31%	18.15%	20.28%	20.82%	21.16%
EPS ²	3.370	2.300	3.940	4.180	4.190	4.553	4.951	5.457
Free Cash Flow ¹	866	802	1,297	1,021	1,474	1,333	1,546	1,730
FCF margin	16.77%	15.02%	20.53%	14.91%	21.57%	20.64%	22.58%	23.63%
FCF Conversion (EBITDA)	65.86%	60.07%	78.61%	49.78%	75.4%	70.71%	74.3%	75.98%
FCF Conversion (Net income)	80.86%	111.54%	107.19%	81.42%	118.87%	101.74%	108.45%	111.69%
Dividend per Share ²	0.6560	0.7200	0.7760	0.8400	-	0.9370	0.9907	1.089
Announcement Date	25/11/19	23/11/20	22/11/21	21/11/22	20/11/23	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: October	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3
Net sales ¹	1,674	1,607	1,718	1,849	1,756	1,717	1,672	1,688	1,658	1,573	1,557	1,670	1,694	1,645	1,662
EBITDA ¹	517	454	503	578	507	473	523	504	464	432	459	521.5	509.4	474	500
EBIT ¹	486	422	471	538	476	440	490	469	428	395	415	472.2	456.9	428.3	441.1
Operating Margin	29.03%	26.26%	27.42%	29.1%	27.11%	25.63%	29.31%	27.78%	25.81%	25.11%	26.65%	28.27%	26.97%	26.03%	26.54%
Earnings before Tax (EBT)	-	-	-	455	410	-	-	-	-	-	-	-	-	-	-
Net income ¹	283	274	329	368	352	302	111	475	348	308	346.2	389.4	396.1	373.3	378.5
Net margin	16.91%	17.05%	19.15%	19.9%	20.05%	17.59%	6.64%	28.14%	20.99%	19.58%	22.23%	23.31%	23.39%	22.69%	22.78%
EPS ²	0.9300	0.9100	1.100	1.230	1.190	1.020	0.3800	1.620	1.180	1.050	1.144	1.339	1.328	1.295	1.311
Dividend per Share ²	0.2100	0.2100	0.2100	0.2100	0.2250	0.2250	-	-	0.2360	-	0.2358	0.2368	0.2380	0.2314	0.2249
Announcement Date	22/02/22	24/05/22	16/08/22	21/11/22	28/02/23	23/05/23	15/08/23	20/11/23	27/02/24	29/05/24	-	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: October	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	1,025	918	1,154	1,716	1,145	878	1,012	2,596
Net Cash position ¹	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	0.7795 x	0.6876 x	0.6994 x	0.8367 x	0.5857 x	0.4657 x	0.4864 x	1.14 x
Free Cash Flow ¹	866	802	1,297	1,021	1,474	1,333	1,546	1,730
ROE (net income / shareholders' equity)	21.2%	21.3%	26%	29.3%	28.3%	24.8%	23.9%	24.5%
ROA (Net income/ Total Assets)	11%	10.7%	13.1%	14.7%	15.1%	12.7%	13.2%	13.2%
Assets ¹	9,742	6,705	9,235	8,502	8,225	10,292	10,834	11,777
Book Value Per Share ²	14.90	15.60	17.80	17.70	19.70	21.40	24.30	28.20
Cash Flow per Share ²	3.210	2.950	4.870	4.370	5.990	5.670	6.560	7.110
Capex ¹	155	119	188	291	298	385	349	334
Capex / Sales	3%	2.23%	2.98%	4.25%	4.36%	5.96%	5.1%	4.56%
Announcement Date	25/11/19	23/11/20	22/11/21	21/11/22	20/11/23	-	-	-

¹USD in Million²USD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Agilent Technologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

131.8 USD

Average target price

139.2 USD

Spread / Average Target

+5.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AGILENT TECHNOLOGIES, INC.	-5.18%	3.85TCr
THERMO FISHER SCIENTIFIC	+7.01%	22TCr
DANAHER CORPORATION	+9.85%	19TCr
INTUITIVE SURGICAL, INC.	+27.51%	15TCr
BOSTON SCIENTIFIC CORPORATION	+31.79%	11TCr
SIEMENS HEALTHINEERS AG	-0.84%	6.28TCr
EDWARDS LIFESCIENCES CORPORATION	+13.93%	5.23TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.85%	4.93TCr
GE HEALTHCARE TECHNOLOGIES INC.	+0.30%	3.54TCr
RESMED, INC.	+22.28%	3.09TCr

Other Advanced Medical Equipment & Technology